{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:31:22Z","timestamp":1772119882108,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004897","name":"Pennsylvania Department of Health","doi-asserted-by":"publisher","award":["Biotechnology Research"],"award-info":[{"award-number":["Biotechnology Research"]}],"id":[{"id":"10.13039\/100004897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004897","name":"Pennsylvania Department of Health","doi-asserted-by":"publisher","award":["Biotechnology Research"],"award-info":[{"award-number":["Biotechnology Research"]}],"id":[{"id":"10.13039\/100004897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004897","name":"Pennsylvania Department of Health","doi-asserted-by":"publisher","award":["Biotechnology Research"],"award-info":[{"award-number":["Biotechnology Research"]}],"id":[{"id":"10.13039\/100004897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Purinergic Signalling"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s11302-023-09930-5","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T23:03:11Z","timestamp":1679439791000},"page":"467-479","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["DT-0111: a novel P2X3 receptor antagonist"],"prefix":"10.1007","volume":"19","author":[{"given":"Amir","family":"Pelleg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Sirtori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Francois","family":"Rolland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anu","family":"Mahadevan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,22]]},"reference":[{"issue":"11","key":"9930_CR1","doi-asserted-by":"publisher","first-page":"e201912475","DOI":"10.1085\/jgp.201912475","volume":"152","author":"JA Nirody","year":"2020","unstructured":"Nirody JA, Budin I, Rangamani P (2020) ATP synthase: Evolution, energetics, and membrane interactions. J Gen Physiol 152(11):e201912475","journal-title":"J Gen Physiol"},{"issue":"104","key":"9930_CR2","doi-asserted-by":"publisher","first-page":"re1","DOI":"10.1126\/scisignal.3104re1","volume":"3","author":"R Corriden","year":"2010","unstructured":"Corriden R, Insel PA (2010) Basal release of ATP: an autocrine-paracrine mechanism for cell regulation. Sci Signal 3(104):re1","journal-title":"Sci Signal"},{"issue":"1","key":"9930_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1113\/expphysiol.2013.071951","volume":"99","author":"G Burnstock","year":"2014","unstructured":"Burnstock G (2014) Purinergic signalling: from discovery to current developments. Exp Physiol 99(1):16\u201334","journal-title":"Exp Physiol"},{"issue":"11","key":"9930_CR4","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1111\/bph.15005","volume":"177","author":"KA Jacobson","year":"2020","unstructured":"Jacobson KA, Delicado EG, Gachet C, Kennedy C, von Kugelgen I, Li B, Miras-Portugal MT, Novak I, Schoneberg T, Perez-Sen R, Thor D, Wu B, Yang Z, Muller CE (2020) Update of P2Y receptor pharmacology: IUPHAR Review 27. Br J Pharmacol 177(11):2413\u20132433","journal-title":"Br J Pharmacol"},{"issue":"3","key":"9930_CR5","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/bph.15299","volume":"178","author":"P Illes","year":"2021","unstructured":"Illes P, Muller CE, Jacobson KA, Grutter T, Nicke A, Fountain SJ, Kennedy C, Schmalzing G, Jarvis MF, Stojilkovic SS, King BF, Di Virgilio F (2021) Update of P2X receptor properties and their pharmacology: IUPHAR Review 30. Br J Pharmacol 178(3):489\u2013514","journal-title":"Br J Pharmacol"},{"key":"9930_CR6","doi-asserted-by":"publisher","first-page":"239821281881749","DOI":"10.1177\/2398212818817494","volume":"2","author":"G Burnstock","year":"2018","unstructured":"Burnstock G (2018) Purine and purinergic receptors. Brain Neurosci Adv 2:2398212818817494","journal-title":"Brain Neurosci Adv"},{"key":"9930_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.neuropharm.2015.12.001","volume":"104","author":"KA Jacobson","year":"2016","unstructured":"Jacobson KA, Muller CE (2016) Medicinal chemistry of adenosine, P2Y and P2X receptors. Neuropharmacology 104:31\u201349","journal-title":"Neuropharmacology"},{"issue":"4","key":"9930_CR8","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1124\/pr.111.005389","volume":"64","author":"G Burnstock","year":"2012","unstructured":"Burnstock G, Brouns I, Adriaensen D, Timmermans JP (2012) Purinergic signaling in the airways. Pharmacol Rev 64(4):834\u2013868","journal-title":"Pharmacol Rev"},{"issue":"Pt 1","key":"9930_CR9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1113\/jphysiol.1996.sp021142","volume":"490","author":"A Pelleg","year":"1996","unstructured":"Pelleg A, Hurt CM (1996) Mechanism of action of ATP on canine pulmonary vagal C fibre nerve terminals. J Physiol 490(Pt 1):265\u2013275","journal-title":"J Physiol"},{"issue":"3\u20134","key":"9930_CR10","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/(SICI)1098-2299(199811\/12)45:3\/4<342::AID-DDR34>3.0.CO;2-P","volume":"45","author":"G Katchanov","year":"1998","unstructured":"Katchanov G, Xu J, Schulman ES, Pelleg A (1998) ATP causes neurogenic bronchoconstriction in the dog. Drug Dev Res 45(3\u20134):342\u2013349","journal-title":"Drug Dev Res"},{"issue":"2","key":"9930_CR11","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1152\/jappl.1996.81.2.964","volume":"81","author":"R Pellegrino","year":"1996","unstructured":"Pellegrino R, Wilson O, Jenouri G, Rodarte JR (1996) Lung mechanics during induced bronchoconstriction. J Appl Physiol (1985) 81(2):964\u201375","journal-title":"J Appl Physiol (1985)"},{"issue":"5","key":"9930_CR12","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/00045391-200209000-00014","volume":"9","author":"A Pelleg","year":"2002","unstructured":"Pelleg A, Schulman ES (2002) Adenosine 5\u2019-triphosphate axis in obstructive airway diseases. Am J Ther 9(5):454\u2013464","journal-title":"Am J Ther"},{"issue":"4","key":"9930_CR13","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.chest.2016.06.045","volume":"150","author":"A Pelleg","year":"2016","unstructured":"Pelleg A, Schulman ES, Barnes PJ (2016) Extracellular Adenosine 5\u2019-Triphosphate in Obstructive Airway Diseases. Chest 150(4):908\u2013915","journal-title":"Chest"},{"key":"9930_CR14","doi-asserted-by":"publisher","first-page":"114319","DOI":"10.1016\/j.bcp.2020.114319","volume":"187","author":"A Pelleg","year":"2021","unstructured":"Pelleg A (2021) Extracellular adenosine 5\u2019-triphosphate in pulmonary disorders. Biochem Pharmacol 187:114319","journal-title":"Biochem Pharmacol"},{"issue":"13","key":"9930_CR15","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1111\/bph.14677","volume":"176","author":"D Richards","year":"2019","unstructured":"Richards D, Gever JR, Ford AP, Fountain SJ (2019) Action of MK-7264 (gefapixant) at human P2X3 and P2X2\/3 receptors and in vivo efficacy in models of sensitisation. Br J Pharmacol 176(13):2279\u20132291","journal-title":"Br J Pharmacol"},{"issue":"9974","key":"9930_CR16","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/S0140-6736(14)61255-1","volume":"385","author":"R Abdulqawi","year":"2015","unstructured":"Abdulqawi R, Dockry R, Holt K, Layton G, McCarthy BG, Ford AP, Smith JA (2015) P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 385(9974):1198\u20131205","journal-title":"Lancet"},{"key":"9930_CR17","doi-asserted-by":"crossref","unstructured":"Wang J, Wang Y, Cui WW, Huang Y, Yang Y, Liu Y, Zhao WS, Cheng XY, Sun WS, Cao P, Zhu MX, Wang R, Hattori M, Yu Y (2018) Druggable negative allosteric site of P2X3 receptors. Proc Natl Acad Sci U S A 115(19):4939-4944","DOI":"10.1073\/pnas.1800907115"},{"key":"9930_CR18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.pupt.2019.03.007","volume":"56","author":"D Garceau","year":"2019","unstructured":"Garceau D, Chauret N (2019) BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration. Pulm Pharmacol Ther 56:56\u201362","journal-title":"Pulm Pharmacol Ther"},{"key":"9930_CR19","doi-asserted-by":"publisher","first-page":"128384","DOI":"10.1016\/j.bmcl.2021.128384","volume":"52","author":"H Kai","year":"2021","unstructured":"Kai H, Horiguchi T, Kameyma T, Onodera N, Itoh N, Fujii Y, Ichihashi Y, Hirai K, Shintani T, Nakamura K, Minami K, Kasai E, Yoneda S, Murakami Y, Ogawa H, Sekimoto R, Shinohara S, Yoshida O, Kurose N (2021) Discovery of clinical candidate Sivopixant (S-600918): Lead optimization of dioxotriazine derivatives as selective P2X3 receptor antagonists. Bioorg Med Chem Lett 52:128384","journal-title":"Bioorg Med Chem Lett"},{"issue":"5","key":"9930_CR20","doi-asserted-by":"publisher","first-page":"2004240","DOI":"10.1183\/13993003.04240-2020","volume":"58","author":"A Morice","year":"2021","unstructured":"Morice A, Smith JA, McGarvey L, Birring SS, Parker SM, Turner A, Hummel T, Gashaw I, Fels L, Klein S, Francke K, Friedrich C (2021) Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study. Eur Respir J 58(5):2004240","journal-title":"Eur Respir J"},{"key":"9930_CR21","doi-asserted-by":"crossref","unstructured":"Friedrich C, Francke K, Birring SS, Van Den Berg JWK, Marsden P, McGarvey L, Turner A, Wielders P, Gashaw I, Klein S, Morice A (2020) Safety and efficacy of P2X3 antagonist BAY 1902607 in refractory chronic cough. Eur Respir J 56\u00a0","DOI":"10.1183\/13993003.congress-2020.4566"},{"key":"9930_CR22","unstructured":"Pelleg A, Mahadaven A, Li J, Morency C (\u00a02022) US Patent No. US 11,440,935 B2, https:\/\/ppubs.uspto.gov\/pubwebapp\/"},{"issue":"7428","key":"9930_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nature11691","volume":"492","author":"J Besnard","year":"2012","unstructured":"Besnard J, Ruda GF, Setola V, Abecassis K, Rodriguiz RM, Huang XP, Norval S, Sassano MF, Shin AI, Webster LA, Simeons FR, Stojanovski L, Prat A, Seidah NG, Constam DB, Bickerton GR, Read KD, Wetsel WC, Gilbert IH, Roth BL, Hopkins AL (2012) Automated design of ligands to polypharmacological profiles. Nature 492(7428):215\u2013220","journal-title":"Nature"},{"issue":"5","key":"9930_CR24","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nsmb.3014","volume":"22","author":"WK Kroeze","year":"2015","unstructured":"Kroeze WK, Sassano MF, Huang XP, Lansu K, McCorvy JD, Giguere PM, Sciaky N, Roth BL (2015) PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome. Nat Struct Mol Biol 22(5):362\u2013369","journal-title":"Nat Struct Mol Biol"},{"issue":"6","key":"9930_CR25","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1089\/adt.2010.0331","volume":"8","author":"XP Huang","year":"2010","unstructured":"Huang XP, Mangano T, Hufeisen S, Setola V, Roth BL (2010) Identification of human Ether-a-go-go related gene modulators by three screening platforms in an academic drug-discovery setting. Assay Drug Dev Technol 8(6):727\u2013742","journal-title":"Assay Drug Dev Technol"},{"issue":"6","key":"9930_CR26","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1038\/sj.bjp.0704591","volume":"135","author":"V Spelta","year":"2002","unstructured":"Spelta V, Jiang LH, Surprenant A, North RA (2002) Kinetics of antagonist actions at rat P2X2\/3 heteromeric receptors. Br J Pharmacol 135(6):1524\u20131530","journal-title":"Br J Pharmacol"},{"issue":"6","key":"9930_CR27","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/j.1476-5381.2010.00796.x","volume":"160","author":"JR Gever","year":"2010","unstructured":"Gever JR, Soto R, Henningsen RA, Martin RS, Hackos DH, Panicker S, Rubas W, Oglesby IB, Dillon MP, Milla ME, Burnstock G, Ford AP (2010) AF-353, a novel, potent and orally bioavailable P2X3\/P2X2\/3 receptor antagonist. Br J Pharmacol 160(6):1387\u20131398","journal-title":"Br J Pharmacol"},{"issue":"4","key":"9930_CR28","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1152\/physrev.00015.2002","volume":"82","author":"RA North","year":"2002","unstructured":"North RA (2002) Molecular physiology of P2X receptors. Physiol Rev 82(4):1013\u20131067","journal-title":"Physiol Rev"},{"issue":"3","key":"9930_CR29","first-page":"1043","volume":"296","author":"M Liu","year":"2001","unstructured":"Liu M, King BF, Dunn PM, Rong W, Townsend-Nicholson A, Burnstock G (2001) Coexpression of P2X(3) and P2X(2) receptor subunits in varying amounts generates heterogeneous populations of P2X receptors that evoke a spectrum of agonist responses comparable to that seen in sensory neurons. J Pharmacol Exp Ther 296(3):1043\u20131050","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"9930_CR30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12890-020-1152-8","volume":"20","author":"A Koarai","year":"2020","unstructured":"Koarai A, Sugiura H, Yamada M, Ichikawa T, Fujino N, Kawayama T, Ichinose M (2020) Treatment with LABA versus LAMA for stable COPD: a systematic review and meta-analysis. BMC Pulm Med 20(1):111","journal-title":"BMC Pulm Med"},{"issue":"1","key":"9930_CR31","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12931-021-01777-x","volume":"22","author":"A Koarai","year":"2021","unstructured":"Koarai A, Yamada M, Ichikawa T, Fujino N, Kawayama T, Sugiura H (2021) Triple versus LAMA\/LABA combination therapy for patients with COPD: a systematic review and meta-analysis. Respir Res 22(1):183","journal-title":"Respir Res"},{"key":"9930_CR32","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.2147\/COPD.S185975","volume":"13","author":"L Vanfleteren","year":"2018","unstructured":"Vanfleteren L, Fabbri LM, Papi A, Petruzzelli S, Celli B (2018) Triple therapy (ICS\/LABA\/LAMA) in COPD: time for a reappraisal. Int J Chron Obstruct Pulmon Dis 13:3971\u20133981","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"24","key":"9930_CR33","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1001\/jama.2021.7872","volume":"325","author":"LHY Kim","year":"2021","unstructured":"Kim LHY, Saleh C, Whalen-Browne A, O\u2019Byrne PM, Chu DK (2021) Triple vs Dual Inhaler Therapy and Asthma Outcomes in Moderate to Severe Asthma: A Systematic Review and Meta-analysis. JAMA 325(24):2466\u20132479","journal-title":"JAMA"},{"issue":"Suppl 1","key":"9930_CR34","first-page":"S59","volume":"115","author":"BJ Undem","year":"2005","unstructured":"Undem BJ, Pelleg A (2005) A-317491 inhibits the activation of guinea-pig pulmonary vagal sensory nerve terminals by \u03b1, \u03b2-methylene-ATP. Clin Immunol 115(Suppl 1):S59-60","journal-title":"Clin Immunol"},{"issue":"12","key":"9930_CR35","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1080\/13543776.2019.1693542","volume":"29","author":"G Marucci","year":"2019","unstructured":"Marucci G, Dal Ben D, Buccioni M, Marti Navia A, Spinaci A, Volpini R, Lambertucci C (2019) Update on novel purinergic P2X3 and P2X2\/3 receptor antagonists and their potential therapeutic applications. Expert Opin Ther Pat 29(12):943\u2013963","journal-title":"Expert Opin Ther Pat"},{"key":"9930_CR36","doi-asserted-by":"publisher","first-page":"175346661987796","DOI":"10.1177\/1753466619877960","volume":"13","author":"A Pelleg","year":"2019","unstructured":"Pelleg A, Xu F, Zhuang J, Undem B, Burnstock G (2019) DT-0111: a novel drug-candidate for the treatment of COPD and chronic cough. Ther Adv Respir Dis 13:1753466619877960","journal-title":"Ther Adv Respir Dis"},{"issue":"6548","key":"9930_CR37","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/377428a0","volume":"377","author":"CC Chen","year":"1995","unstructured":"Chen CC, Akopian AN, Sivilotti L, Colquhoun D, Burnstock G, Wood JN (1995) A P2X purinoceptor expressed by a subset of sensory neurons. Nature 377(6548):428\u2013431","journal-title":"Nature"},{"issue":"5","key":"9930_CR38","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1113\/jphysiol.2014.281014","volume":"593","author":"A Vandenbeuch","year":"2015","unstructured":"Vandenbeuch A, Larson ED, Anderson CB, Smith SA, Ford AP, Finger TE, Kinnamon SC (2015) Postsynaptic P2X3-containing receptors in gustatory nerve fibres mediate responses to all taste qualities in mice. J Physiol 593(5):1113\u20131125","journal-title":"J Physiol"},{"issue":"3","key":"9930_CR39","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1007\/s13311-020-00934-2","volume":"17","author":"JL Krajewski","year":"2020","unstructured":"Krajewski JL (2020) P2X3-Containing Receptors as Targets for the Treatment of Chronic Pain. Neurotherapeutics 17(3):826\u2013838","journal-title":"Neurotherapeutics"},{"key":"9930_CR40","doi-asserted-by":"crossref","unstructured":"Jarvis MF, Burgard EC, McGaraughty S, Honore P, Lynch K, Brennan TJ, Subieta A, Van Biesen T, Cartmell J, Bianchi B, Niforatos W, Kage K, Yu H, Mikusa J, Wismer CT, Zhu CZ, Chu K, Lee CH, Stewart AO, Polakowski J, Cox BF, Kowaluk E, Williams M, Sullivan J, Faltynek C (2002) A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2\/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat. Proc Natl AcadSci U S A 99(26):17179-17184","DOI":"10.1073\/pnas.252537299"},{"issue":"7623","key":"9930_CR41","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/nature19367","volume":"538","author":"SE Mansoor","year":"2016","unstructured":"Mansoor SE, Lu W, Oosterheert W, Shekhar M, Tajkhorshid E, Gouaux E (2016) X-ray structures define human P2X(3) receptor gating cycle and antagonist action. Nature 538(7623):66\u201371","journal-title":"Nature"},{"issue":"1","key":"9930_CR42","doi-asserted-by":"publisher","first-page":"53","DOI":"10.4155\/ppa.13.70","volume":"3","author":"H Bolcskei","year":"2014","unstructured":"Bolcskei H, Farkas B (2014) P2X3 and P2X2\/3 receptor antagonists. Pharm Pat Anal 3(1):53\u201364","journal-title":"Pharm Pat Anal"},{"issue":"7","key":"9930_CR43","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1080\/13543776.2022.2069010","volume":"32","author":"C Dane","year":"2022","unstructured":"Dane C, Stokes L, Jorgensen WT (2022) P2X receptor antagonists and their potential as therapeutics: a patent review (2010\u20132021). Expert Opin Ther Pat 32(7):769\u2013790","journal-title":"Expert Opin Ther Pat"},{"issue":"3","key":"9930_CR44","doi-asserted-by":"publisher","first-page":"R651","DOI":"10.1152\/ajpregu.00553.2004","volume":"288","author":"J Xu","year":"2005","unstructured":"Xu J, Kussmaul W, Kurnik PB, Al-Ahdav M, Pelleg A (2005) Electrophysiological-anatomic correlates of ATP-triggered vagal reflex in the dog. V. Role of purinergic receptors. Am J Physiol Regul Integr Comp Physiol 288(3):R651\u2013R655","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"5753","key":"9930_CR45","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1126\/science.1118435","volume":"310","author":"TE Finger","year":"2005","unstructured":"Finger TE, Danilova V, Barrows J, Bartel DL, Vigers AJ, Stone L, Hellekant G, Kinnamon SC (2005) ATP signaling is crucial for communication from taste buds to gustatory nerves. Science 310(5753):1495\u20131499","journal-title":"Science"},{"issue":"2","key":"9930_CR46","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/cne.22000","volume":"514","author":"Y Ishida","year":"2009","unstructured":"Ishida Y, Ugawa S, Ueda T, Yamada T, Shibata Y, Hondoh A, Inoue K, Yu Y, Shimada S (2009) P2X(2)- and P2X(3)-positive fibers in fungiform papillae originate from the chorda tympani but not the trigeminal nerve in rats and mice. J Comp Neurol 514(2):131\u2013144","journal-title":"J Comp Neurol"}],"container-title":["Purinergic Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-023-09930-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11302-023-09930-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-023-09930-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T03:14:24Z","timestamp":1695870864000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11302-023-09930-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,22]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["9930"],"URL":"https:\/\/doi.org\/10.1007\/s11302-023-09930-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2382427\/v1","asserted-by":"object"}]},"ISSN":["1573-9538","1573-9546"],"issn-type":[{"value":"1573-9538","type":"print"},{"value":"1573-9546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,22]]},"assertion":[{"value":"15 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Drs. Pelleg and Mahadevan are the CEOs of Danmir Therapeutics, LLC and Organix, Inc. respectively, which together are developing DT-0111 as a drug candidate for the treatment of several pulmonary disorders. Drs. Sirtori and Rolland declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}